Former Vice President, National Account Team Lead, U.S. Market Access, Novartis
Laura Randa is a respected thought leader within the pharmaceutical industry, addressing the payer sector and leaving an indelible mark across many different organizations. Laura recently joined Novartis as VP, national accounts team lead, a strategic role in which she works collaboratively with the Medical, HEOR, Public Policy, Finance, Brand, and Legal teams to support the business goals of Novartis’ US Pharma business through securing favorable formulary access with patient affordability in all relevant segments across the entire portfolio.
In her previous role as head of payer engagement at Regeneron, Laura transformed how the company launches and markets products in the managed markets space. She focused on creating transparent, mutually beneficial manufacturer/payer relationships that drove strong gains in revenue, market share and profits all while enabling affordable access to medicines.
Also while at Regeneron, Laura also initiated a campaign to educate Regeneron’s C-suite executives on how managed care entities operate and thus created an enterprise-wide strategy that allowed the company to engage with payers to develop fair pricing, rapid formulary access, and appropriate reimbursement for its products. Ultimately, she was responsible for leading the executive dialogue between her company, its alliance partners, and corporate executives of payers, which led to a successful launch of Regeneron’s new injectable product to treat atopic dermatitis, Dupixent®.
Laura’s experience in leading teams and creating a positive, productive environment was also fundamental in creating a productive alliance with Sanofi, Regeneron’s corporate partner in several recent launches. She continually inspires her teammates by effectively working cross-functionally and making an impact at all levels. Laura has been successful in building a strong, effective team which has shown to be critical for business success. Her high performing teams consistently have been able to impact the company’s bottom line through high productivity, and a positive culture.
Beginning early in the R&D cycle of an investigational product, Laura focuses on ways to effectively improve competitive positioning – by building innovative, strategic collaborations with internal and external stakeholders that deliver access to new markets s and inserting payer feedback on appropriate patient selection and indication into study design.
Described as an industry “connector,” Laura has been instrumental in helping to build bridges with other companies to help all parties increase knowledge, gain external focus and build initiatives that are built with mutual purpose. Most recently, she was Regeneron’s sponsor for a cross-functional initiative to develop alliance guidance for the FDA Draft Guidance on Health Care Economic Information (HCEI) Communication. She worked tirelessly to align internally and with the company’s two alliance partners to develop an approach for presenting proactive economic data.
Now, at Novartis, Laura will execute value based pricing for value based access, leading the cross-functional team in the negotiation and implementation of formulary access, working towards affordable out-of-pocket for patients. Admired for her creative thinking and constant innovation, she helps team members stand out for their contributions to driving solutions aimed to enhancing healthcare connections.
Laura earned her undergraduate degree at The Ohio State University and her M.B.A. from University of Delaware.